What is the recommended dosing of filgrastim (Neupogen) for chemotherapy‑induced neutropenia, stem‑cell transplantation, and peripheral‑blood stem‑cell mobilization, including pediatric dose limits and adjustments for renal or hepatic impairment?

Neupogen Dosing

For chemotherapy-induced neutropenia, administer filgrastim (Neupogen) at 5 mcg/kg/day subcutaneously starting 1-3 days after chemotherapy and continue until ANC reaches 10,000/mm³; for stem cell mobilization, use 10 mcg/kg/day starting 4 days before leukapheresis; and for bone marrow transplant, use 10 mcg/kg/day starting at least 24 hours after transplant. 1, 2

Chemotherapy-Induced Neutropenia

Standard Dosing:

• Dose: 5 mcg/kg/day subcutaneously 1, 2
• Timing: Start 1-3 days after chemotherapy completion (must be ≥24 hours post-chemotherapy) 1, 2
• Duration: Continue daily until ANC reaches 10,000/mm³ after the expected nadir, typically up to 2 weeks 2
• Route: Subcutaneous injection is preferred 1

Dose Adjustments:

• May increase by 5 mcg/kg increments per chemotherapy cycle based on severity and duration of ANC nadir 2
• Discontinue if ANC exceeds 10,000/mm³ after the nadir 2
• Phase 3 trials demonstrated efficacy at 4-8 mcg/kg/day 2

Critical Timing Caveat: Never administer within 24 hours before chemotherapy, as this can worsen outcomes 1, 2. The guideline emphasizes continuing prophylaxis through all chemotherapy cycles—women receiving pegfilgrastim only during the first 2 cycles had 36% febrile neutropenia versus 10% when given all 6 cycles 1.

Stem Cell Mobilization (PBPC Collection)

Mobilization Dosing:

• Dose: 10 mcg/kg/day subcutaneously 1, 2
• Timing: Start 4 days before first leukapheresis and continue until last leukapheresis 1, 2
• Duration: Typically 6-7 days with leukapheresis on days 5,6, and 7 2

Monitoring: Check neutrophil counts after 4 days; consider dose modification if WBC exceeds 100,000/mm³ 2

Evidence Note: Research comparing 10 mcg/kg once daily versus 5 mcg/kg twice daily showed the twice-daily regimen achieved higher CD34+ cell yields (5.4 vs 4.0 × 10⁶/kg, P=0.007) with 96% versus 68% reaching target with one apheresis 3. However, more recent data suggests once-daily 10 mcg/kg is equally effective 4. The FDA label and ASCO guidelines support 10 mcg/kg/day as a single dose for mobilization 1, 2.

Bone Marrow/Stem Cell Transplantation

Post-Transplant Dosing:

• Initial dose: 10 mcg/kg/day IV (4-24 hour infusion) or continuous 24-hour SC infusion 2
• Timing: Start ≥24 hours after chemotherapy AND ≥24 hours after bone marrow infusion 2

Titration Algorithm:

1. When ANC >1,000/mm³ for 3 consecutive days → Reduce to 5 mcg/kg/day
2. If ANC remains >1,000/mm³ for 3 more consecutive days → Discontinue
3. If ANC drops <1,000/mm³ → Resume at 5 mcg/kg/day
4. If ANC drops <1,000/mm³ while on 5 mcg/kg/day → Increase back to 10 mcg/kg/day 2

Pediatric Dosing

Weight-Based Dosing:

• Same mg/kg dosing as adults (5 mcg/kg/day for chemotherapy, 10 mcg/kg/day for mobilization) 1, 5
• Pegfilgrastim: 100 mcg/kg single dose (but NOT for children <45 kg per FDA label) 1, 5

Pediatric Evidence: A 2025 randomized trial in children showed pegfilgrastim 100 mcg/kg reduced febrile neutropenia incidence from 18% to 8% (P=0.01) compared to daily filgrastim 6. However, the ASCO guideline explicitly states pegfilgrastim 6 mg formulation should not be used in children weighing <45 kg 1.

Important Pediatric Caveat: Routine use of G-CSF is NOT recommended for children with acute myeloid leukemia or acute lymphoblastic leukemia, as it does not decrease infectious complications and has theoretical concerns about stimulating leukemic blast growth 1.

Severe Chronic Neutropenia

Starting Doses:

• Congenital neutropenia: 6 mcg/kg twice daily (BID) subcutaneously 2
• Idiopathic or cyclic neutropenia: 5 mcg/kg once daily subcutaneously 2

Dose Adjustments:

• Individualize based on clinical course AND ANC (not ANC alone) 2
• Median maintenance doses: 6.0 mcg/kg (congenital), 2.1 mcg/kg (cyclic), 1.2 mcg/kg (idiopathic) 2
• Rare cases of congenital neutropenia may require ≥100 mcg/kg/day 2

Renal and Hepatic Impairment

No dose adjustments are specified in the FDA label or ASCO guidelines for renal or hepatic impairment [1-2. The evidence provided does not address this population, suggesting standard dosing applies unless clinical judgment dictates otherwise based on individual patient factors.

Administration Details

Route Preferences:

• Subcutaneous is preferred for all indications 1
• IV infusion acceptable for chemotherapy (15-30 minutes) or transplant settings (4-24 hours) 2

Storage and Handling:

• Refrigerate at 2-8°C (36-46°F) 2
• May be at room temperature maximum 24 hours before use 2
• Avoid shaking 2

Dilution (if needed):

• Use 5% dextrose only (never saline—product may precipitate) 2
• If diluting to 5-15 mcg/mL, add albumin to final concentration of 2 mg/mL to prevent adsorption 2
• Never dilute to <5 mcg/mL 2

Biosimilar Equivalency

Filgrastim-sndz and tbo-filgrastim are dosed identically to reference filgrastim (5 mcg/kg/day for chemotherapy) and can be used interchangeably based on cost and availability 1, 7, 8. Research confirms biosimilar Nivestim® is as effective as Neupogen® for stem cell mobilization 8.